Skip to main content
SpringerLink
Log in

Adrenal lesions in acromegaly: Do metabolic aspects and aryl hydrocarbon receptor interacting protein gene have a role? Evaluation at baseline and after long-term follow-up

  • Original Articles
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background: Adrenal lesions are discovered in acromegaly more frequently than in general population, without relationship with primary disease. Some patients, carriers of aryl hydrocarbon receptor interacting protein (AIP) gene mutations, developed an adrenal neoplasm. Aim: To evaluate the role of metabolic and genetic aspects and the follow-up of adrenal nodules in acromegaly. Material and methods: We studied 69 acromegalic patients (30 male and 39 female, 56±15 yr) who had been referred to the Endocrinology Unit of Padua. In all patients we determined body mass index (BMI) and waist-to-hip ratio (WHR); we performed an oral glucose tolerance test (OGTT) whenever possible. If adrenal computed tomography revealed a lesion, the patient underwent an endocrine and genetic study. Results: Adrenal lesions were identified in 14 patients and were not related to gender, duration of disease, GH or IGF-I concentrations, basal and after-OGTT glucose and insulin levels, log(HOMA-IR) and Quantitative Insulin Sensitivity Check Index (QUICKI) values, whereas BMI and WHR were higher in patients with adrenal lesions. Baseline endocrine and radiological study revealed benign lesions; during mean 4-yr follow-up none of the patients showed hormone excess, even though some lesions increased in size. We did not find any mutation in AIP gene, except heterozygous silent alteration (T48T). Conclusions: The frequency of non-functioning adrenal lesions in acromegaly is not associated with the considered aspects, except BMI and WHR. The prolonged follow-up showed that these lesions have a tendency to increase in size independently of the control of acromegaly, so a morphological follow-up is recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bertherat J, Mosnier-Pudar H, Bertagna X. Adrenal incidentalomas. Curr Opin Oncol 2001, 14: 58–63.

    Article  Google Scholar 

  2. Mantero F, Albiger N. A comprehensive approach to adrenal incidentalomas. Arq Bras Endocrinol & Metab 2004, 48: 583–91.

    Article  Google Scholar 

  3. Beuschlein F. Adrenal incidentalomas: presentation and clinical work-up. Horm Res, 2007, 68: 191–94.

    Article  PubMed  Google Scholar 

  4. Singh PK, Buch HN. Adrenal incidentaloma: evaluation and management. J Clin Pathol 2008, 61: 1168–73.

    Article  PubMed  CAS  Google Scholar 

  5. Melmed S. Medical progress: Acromegaly. N Engl J Med 2006, 355: 2558–73.

    Article  PubMed  CAS  Google Scholar 

  6. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly; epidemiology, pathogenesis, and management. Endocr Rev 2004, 25: 102–52.

    Article  PubMed  CAS  Google Scholar 

  7. Jenkins PJ, Mukherjee A, Shalet SM. Does growth hormone cause cancer? Clin Endocrinol 2006, 64: 115–21.

    Article  CAS  Google Scholar 

  8. Loeper S, Ezzat S. Acromegaly: Re-thinking the cancer risk. Rev Endocr Metab Disord 2008, 9: 41–58.

    Article  PubMed  CAS  Google Scholar 

  9. Tita P, Ambrosio MR, Scollo C, et al. High prevalence of differentiated thyroid carcinoma in acromegaly. Clin Endocrinol (Oxf) 2005, 63: 161–7.

    Article  Google Scholar 

  10. Colao AM, Pivonello R, Auriemma RS, et al. The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients. J Clin Endocrinol Metab 2007, 92: 3854–60.

    Article  PubMed  CAS  Google Scholar 

  11. Rokkas T, Pistiolas D, Sechopoulos P, MargantinisG, Koukoulis G. Risk of colorectal neoplasm in patients with acromegaly: A metaanalysis. World J Gastroenterol 2008, 14: 3484–9.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Scaroni C, Selice R, Benedini S, et al. Adrenal morpho-functional alterations in patients with acromegaly. J Endocrinol Invest 2008, 31: 602–6.

    Article  PubMed  CAS  Google Scholar 

  13. Vierimaa O, Georgitsi M, Lehtonen R, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006, 312: 1228–30.

    Article  PubMed  CAS  Google Scholar 

  14. Daly AF, Vanbellinghen JF, Khoo SK, et al. Aryl Hydrocarbon Receptor Interacting Protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab 2007, 92: 1891–6.

    Article  PubMed  CAS  Google Scholar 

  15. Georgitsi M, Karhu A, Winqvist R, et al. Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers. Br J Cancer 2007, 96: 352–6.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  16. Raitila A, Georgitsi M, Karhu A, et al. No evidence of somatic aryl hydrocarbon receptor interacting protein mutations in sporadic endocrine neoplasia. Endocr Relat Cancer 2007, 14: 901–6.

    Article  PubMed  CAS  Google Scholar 

  17. Raitila A, Georgitsi M, Bonora E, et al. Aryl hydrocarbon receptor interacting protein mutations seem not to associate with familial non-medullary thyroid cancer. J Endocrinol Invest 2009, 32: 426–9.

    Article  PubMed  CAS  Google Scholar 

  18. Cazabat L, Libè, R, Perlemoine K, et al. Germline inactivating mutations of the Aryl Hydrocarbon Receptor-Interacting Protein gene in a large cohort of sporadic acromegaly: mutations are found in a Subset of young patients with macroadenomas. Eur J Endocrinol 2007, 157: 1–8.

    Article  PubMed  CAS  Google Scholar 

  19. Leontiou CA, Gueorguiev M, Van Der Spuy J, et al. The role of the AIP gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 2008, 93: 2390–1.

    Article  PubMed  CAS  Google Scholar 

  20. Toledo RA, Mendonca BB, Fragoso MC, et al. Isolated familial somatotropinoma: 11q13-loh and gene/protein expression analysis suggests a possible involvement of aip also in non-pituitary tumorigenesis. Clinics (Sao Paulo) 2010, 65: 407–15.

    Article  Google Scholar 

  21. Cordero RA, Barkan AL. Current diagnosis of acromegaly. Rev Endocr Metab Disord 2008, 9: 13–9.

    Article  PubMed  Google Scholar 

  22. Grottoli S, Razzore P, Gaia D, et al. Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly. J Endocrinol Invest 2003, 26: 123–27.

    Article  PubMed  CAS  Google Scholar 

  23. Friedrich N, Alte D, Volzke H, et al. Reference ranges of serum IGF-1 and IGFBP-3 levels in a general adult population results of the Study of Health in Pomerania (SHIP). Growth Horm IGF Res 2008, 18: 228–37.

    Article  PubMed  CAS  Google Scholar 

  24. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009, 94: 1509–17.

    Article  PubMed  CAS  Google Scholar 

  25. Lacroix A. ACTH-independent macronodular adrenal hyperplasia. Best Pract ResClin Endocrinol Metab 2009, 232: 245–59.

    Article  CAS  Google Scholar 

  26. Terzolo M, Bovio S, Pia A, et al. Subclinical Cushing’s syndrome. Arq Bras Endocrinol Metabol 2007, 51: 1272–9.

    Article  PubMed  Google Scholar 

  27. Terzolo M, Bovio S, Pia A, Reimondo G, Angeli G. Management of adrenal incidentaloma. Best Pract Res Clin Endocrinol Metab 2009, 23: 233–43.

    Article  PubMed  Google Scholar 

  28. Wallace TM, Levy JC, Matthews DR. Use and Abuse of HOMA Modeling. Diabetes Care 2004, 27: 1487–95.

    Article  PubMed  Google Scholar 

  29. Bravata DM, Wellsa CK, Concato J, Kernan WN, Brass LM, Gulanski BI. Two measures of insulin sensitivity provided similar information in a U.S. population. J Clin Epidemiol 2004, 57: 1214–7.

    Article  Google Scholar 

  30. Chen H, Sullivan G, Quon MJ. Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model. Diabetes 2005, 54: 1914–25.

    Article  PubMed  CAS  Google Scholar 

  31. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008, 294, E15–26.

    Article  PubMed  CAS  Google Scholar 

  32. Mancia G, De Backer G, Dominiczak A, et al. ESH-ESC Practice guidelines for the management of arterial hypertension. ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007, 25: 1751–62.

    CAS  Google Scholar 

  33. Grumbach MM, Biller BMK, Braunstein GD, et al. Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann Intern Med 2003, 138: 424–9.

    Article  PubMed  Google Scholar 

  34. Occhi G, Jaffrain-Rea ML, Trivellin G, et al. TThe R304X mutation of the aryl hydrocarbon receptor interacting protein gene in familial isolated pituitary adenomas: Mutational hot-spot or founder effect? J Endocrinol Invest. 2010, 33: 800–5.

    Article  PubMed  CAS  Google Scholar 

  35. Occhi G, Trivellin G, Ceccato F, et al. Prevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasia. Eur J Endocrinol 2010, 163: 369–76.

    Article  PubMed  CAS  Google Scholar 

  36. Mantero F, Terzolo M, Arnaldi, G, et al. A survey on adrenal incidentaloma in Italy. J Clin Endocrinol Metab 2000, 85: 637–44.

    PubMed  CAS  Google Scholar 

  37. Rossi R, Tauchmanova L, Luciano A, et al. Subclinical Cushing’s syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab 2000, 85: 1440–8.

    PubMed  CAS  Google Scholar 

  38. Terzolo M, Pia A, Ali A, et al. Adrenal incidentalomas: a new cause of the metabolic syndrome? J Clin Endocrinol Metab 2002, 87: 998–1003.

    Article  PubMed  CAS  Google Scholar 

  39. Ryu S, Sung KC, Chang Y, Lee WJ, Rhee EJ. Spectrum of insulin sensitivity in the Korean population. Metabolism 2005, 54: 1644–51.

    Article  PubMed  CAS  Google Scholar 

  40. Rossi GP, Sticchi D, Giuliani L, et al. Adiponectin receptor expression in the human adrenal cortex and aldosterone-producing adenomas. Int J Mol Med 2006, 17: 975–80.

    PubMed  CAS  Google Scholar 

  41. Menendez JA, Vazquez-Martin A, Ortega FJ, Fernandez-Real JM. Fatty acid synthase: association with insulin resistance, type 2 diabetes, and cancer. Clin Chem 2009, 55: 425–38.

    Article  PubMed  CAS  Google Scholar 

  42. Ermetici F, Malavazos AE, Corbetta S., et al. Adipokine levels and cardiovascular risk in patients with adrenal incidentaloma. Metabolism 2007, 56: 686–92.

    Article  PubMed  CAS  Google Scholar 

  43. De Ferranti S, Mozaffarian D. The Perfect Storm: Obesity, Adipocyte Dysfunction, and Metabolic Consequences. Clin Chem 2008, 54: 945–55.

    Article  PubMed  CAS  Google Scholar 

  44. Sucunza N, Barahona MJ, Resmini E, et al. Gender dimorphism in body composition abnormalities in acromegaly: males are more affected than females. Eur J Endocrinol 2008, 159: 773–9.

    Article  PubMed  CAS  Google Scholar 

  45. Katznelson L. Alterations in body composition in acromegaly. Pituitary 2009, 12: 136–42.

    Article  PubMed  CAS  Google Scholar 

  46. Barzon L, Sonino N, Fallo F, Palù G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 2003, 149: 273–85.

    Article  PubMed  CAS  Google Scholar 

  47. Barzon L, Scaroni C, Sonino N, et al. Incidentally discovered adrenal tumors: endocrine and Scintigraphic Correlates. J Clin Endocrinol Metab 1998, 83. 55–62.

    PubMed  CAS  Google Scholar 

  48. Barlaskar FM, Hammer GD. The molecular genetics of adrenocortical carcinoma. Rev Endocr Metab Disord 2007, 8: 343–48.

    Article  PubMed  Google Scholar 

  49. Soon PSH, McDonald KL, Robinson BG, Sidhu SB. Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist 2008, 13: 548–61.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrinology Unit, Department of Medical and Surgical Sciences, University of Padua, Via Ospedale 105, 35128, Padua, Italy

    F. Ceccato, G. Occhi, N. M. Albiger, S. Rizzati, S. Ferasin, G. Trivellin, F. Mantero & Carla Scaroni MD

Authors
  1. F. Ceccato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Occhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. M. Albiger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Rizzati
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Ferasin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Trivellin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F. Mantero
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Carla Scaroni MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carla Scaroni MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ceccato, F., Occhi, G., Albiger, N.M. et al. Adrenal lesions in acromegaly: Do metabolic aspects and aryl hydrocarbon receptor interacting protein gene have a role? Evaluation at baseline and after long-term follow-up. J Endocrinol Invest 34, 353–360 (2011). https://doi.org/10.1007/BF03347459

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03347459

Key-words

Search

Navigation